Resources from the same session
LBA65 - First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743
Presenter: Solange Peters
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1170O - An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Characterisation of PORT efficacy in lung ART (IFCT-0503, UK NCRI, SAKK)
Presenter: Cécile Le Pechoux
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA66 - Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial
Presenter: Nicolas Girard
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA42 - COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC
Presenter: Alexandre Martinez-Marti
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
Invited Discussant 1170O and LBA65
Presenter: Pilar Garrido Lopez
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Pilar Garrido Lopez
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Oliver Gautschi
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast